Just Healthcare

Just Healthcare

Share this post

Just Healthcare
Just Healthcare
Favorable Outcomes With Perioperative Immunotherapy in Resectable NSCLC

Favorable Outcomes With Perioperative Immunotherapy in Resectable NSCLC

Large real-world study finds neoadjuvant and adjuvant chemoimmunotherapy improve survival in stage II–IIIA lung cancer

Naveen Sankar S's avatar
Naveen Sankar S
Jul 02, 2025
∙ Paid
3

Share this post

Just Healthcare
Just Healthcare
Favorable Outcomes With Perioperative Immunotherapy in Resectable NSCLC
Share
Generated image

Topline

A nationwide retrospective cohort study of over 1,300 patients with resectable stage II–IIIA NSCLC found that perioperative chemoimmunotherapy significantly improves 18-month distant metastasis–free survival (DMFS), yet remains underused, with fewer than 30% of eligible patients receiving it.

Study Details

Non–small cell lung cancer (NSCLC) remains…

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Just Healthcare
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share